Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDORA: Pembrolizumab with Chemotherapy in Advanced Merkel Cell Carcinoma
NCT06086288Phase 2Not yet recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Merkel cell carcinoma (MCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06086288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086288.